Action of Synbiotics on Irradiated GI Mucosa in Rectal Cancer Treatment (FIPIREX)
Primary Purpose
Rectal Cancer
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Oat bran
Oat bran and blueberry husks
No oral supplementation
Sponsored by
About this trial
This is an interventional prevention trial for Rectal Cancer focused on measuring radiotherapy, probiotics
Eligibility Criteria
Inclusion Criteria:
- Rectal cancer/Adenocarcinoma recti
- Informed Consent explained orally and written, understood, agreed and signed
Exclusion Criteria:
- Diabetes Mellitus
- Inflammatory bowel disease
- Previous radiation to pelvis area
- Ongoing steroid or immunosuppressive therapy
- Ongoing antibiotics therapy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Other
Arm Label
Oat bran
Oat bran and blueberry husks
No oral supplementation
Arm Description
45 g oat bran
13 g freeze dried blueberry husks and 22 g oat bran + probiotic bacteria.
No oral supplementation.
Outcomes
Primary Outcome Measures
Action of synbiotics on irradiated GI mucosa in rectal cancer treatment
Reaction of gastrointestinal mucosa in a clinical setting in patients with preoperative radiotherapy treatment of rectal cancer pre-treated with either a probiotic bacteria, blueberry husks and oat bran, oat bran only or no pre-treatment at all, measured by analysis of bacterial diversity.
Action of synbiotics on irradiated GI mucosa in rectal cancer treatment
Reaction of gastrointestinal mucosa in a clinical setting in patients with preoperative radiotherapy treatment of rectal cancer pre-treated with either a probiotic bacteria, blueberry husks and oat bran, oat bran only or no pre-treatment at all, measured by analysis of inflammation.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03420443
Brief Title
Action of Synbiotics on Irradiated GI Mucosa in Rectal Cancer Treatment
Acronym
FIPIREX
Official Title
Randomized Clinical Trial of Effects of Synbiotics on Intestinal Microbiota in Patients Undergoing Short-course Preoperative Radiotherapy During Treatment of Rectal Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
November 2008 (undefined)
Primary Completion Date
November 2015 (Actual)
Study Completion Date
November 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Region Skane
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study is to investigate how bacteria and fibre interact with the epithelial cells of the gastrointestinal mucosa to reduce inflammation and to diminish tissue damage caused by radiation therapy to patients diagnosed with rectal cancer.
Detailed Description
Thirty patients diagnosed with rectal cancer receiving short term radiation therapy 25 Gray (Gy) during one week preoperatively will be examined. The patients will be divided into three groups with ten patients in each group. One control group without no treatment/study product, one group receiving a test product of 45 g of oat bran and freezing medium only, and one group having a probiotic bacteria, Lactobacillus plantarum HEAL 19 (1010 CFU/g), freezed dried blueberry husks (13 g) and oat bran (22 g), corresponding to 8 g fibre per day in each of the two treated groups. The patients will consume the test product once a day 1 week before and during radiotherapy (2 weeks in total). Mucosal biopsies for microflora analysis and blood samples for analysis of SCFAs and cytokines will be collected at inclusion as well as faecal samples. After radiation therapy, at surgery, blood samples, faecal samples and mucosal biopsies are collected. Fresh faecal samples, blood samples and mucosal biopsies are stored at -80°C until analysis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rectal Cancer
Keywords
radiotherapy, probiotics
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Oat bran
Arm Type
Experimental
Arm Description
45 g oat bran
Arm Title
Oat bran and blueberry husks
Arm Type
Experimental
Arm Description
13 g freeze dried blueberry husks and 22 g oat bran + probiotic bacteria.
Arm Title
No oral supplementation
Arm Type
Other
Arm Description
No oral supplementation.
Intervention Type
Dietary Supplement
Intervention Name(s)
Oat bran
Intervention Description
45 g oat bran.
Intervention Type
Dietary Supplement
Intervention Name(s)
Oat bran and blueberry husks
Intervention Description
13 g freeze dried blueberry husks and 22 g oat bra + probiotic bacteria.
Intervention Type
Dietary Supplement
Intervention Name(s)
No oral supplementation
Intervention Description
No oral supplementation.
Primary Outcome Measure Information:
Title
Action of synbiotics on irradiated GI mucosa in rectal cancer treatment
Description
Reaction of gastrointestinal mucosa in a clinical setting in patients with preoperative radiotherapy treatment of rectal cancer pre-treated with either a probiotic bacteria, blueberry husks and oat bran, oat bran only or no pre-treatment at all, measured by analysis of bacterial diversity.
Time Frame
2 weeks
Title
Action of synbiotics on irradiated GI mucosa in rectal cancer treatment
Description
Reaction of gastrointestinal mucosa in a clinical setting in patients with preoperative radiotherapy treatment of rectal cancer pre-treated with either a probiotic bacteria, blueberry husks and oat bran, oat bran only or no pre-treatment at all, measured by analysis of inflammation.
Time Frame
2 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Rectal cancer/Adenocarcinoma recti
Informed Consent explained orally and written, understood, agreed and signed
Exclusion Criteria:
Diabetes Mellitus
Inflammatory bowel disease
Previous radiation to pelvis area
Ongoing steroid or immunosuppressive therapy
Ongoing antibiotics therapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bengt Jeppsson, Prof
Organizational Affiliation
University of Lund, Sweden
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Action of Synbiotics on Irradiated GI Mucosa in Rectal Cancer Treatment
We'll reach out to this number within 24 hrs